ASCO 2026 Day 2 Highlights: Cell Therapy, Lung Cancer, and Late-Stage Oncology Data
- 5 hours ago
- 3 min read
ASCO 2026 continued to deliver important clinical updates on Day 2, with presentations spanning cell therapy, lung cancer, breast cancer, gastrointestinal tumors, and rare diseases.
While ADCs remained an important part of the meeting, Day 2 highlighted growing momentum behind engineered cell therapies, precision oncology approaches, and several late-stage studies that could influence future standards of care.
Cell Therapy Continues Expanding Beyond Hematology
Immatics ($IMTX) presented Phase 1a data for IMA203CD8, a PRAME-directed TCR-T therapy in ovarian cancer.
Cell therapies have historically achieved their greatest success in hematologic malignancies. Progress in solid tumors remains one of the biggest challenges in oncology, making continued development of PRAME-targeted TCR therapies particularly noteworthy.
Autolus ($AUTL) also reported updated data for obe-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, reinforcing the growing role of engineered cell therapies in hematologic cancers.
Lung Cancer Remains a Precision Oncology Showcase
Several Day 2 presentations focused on increasingly refined patient populations within lung cancer.
BioNTech ($BNTX) reported Phase 2/3 data for its PD-L1/VEGF-A bispecific antibody combined with chemotherapy in first-line NSCLC.
Black Diamond Therapeutics ($BDTX) presented data for silveterinib in non-classical EGFR-mutated NSCLC, while AstraZeneca ($AZN) explored biomarker-selected populations involving STK11, KEAP1, and KRAS mutations.
Together, these studies reflect the continued evolution of precision oncology toward increasingly defined molecular subgroups.
Important Phase 3 Updates Across Oncology
Several late-stage studies reported meaningful results.
Merck ($MRK) presented final analyses from KEYNOTE-522, reinforcing the role of pembrolizumab in high-risk early-stage triple-negative breast cancer.
Novartis ($NVS) reported additional insights from NATALEE, one of the most important studies supporting ribociclib in HR+/HER2- early breast cancer.
Pfizer ($PFE) presented TALAPRO-3 data in HRR-altered metastatic castration-sensitive prostate cancer, while Incyte ($INCY) reported Phase 3 data from frontMIND evaluating tafasitamab in newly diagnosed high-risk DLBCL.
Rare and Difficult-to-Treat Tumors Remain Active Areas of Innovation
Cogent Biosciences ($COGT) reported Phase 3 results for bezuclastinib in gastrointestinal stromal tumors (GIST), while GSK ($GSK) presented data for velzatinib in KIT-mutant GIST.
Immunome ($IMNM) reported Phase 3 data for varegacestat in progressing desmoid tumors.
Inhibrx ($INBX) also presented data for ozekibart in conventional chondrosarcoma, highlighting continued innovation in rare oncology indications.
Catalysts We Will Be Watching
• $IMTX – Continued development of PRAME-directed TCR-T therapy in solid tumors
• $BNTX – Progress of its bispecific antibody strategy in first-line NSCLC
• $MRK – Ongoing impact of KEYNOTE-522 on breast cancer treatment standards
• $PFE – Expansion opportunities following TALAPRO-3
• $COGT – Regulatory and commercial implications of Phase 3 GIST data
Bottom Line
Day 2 reinforced four major themes:
✔ Cell therapy continues expanding into new settings ($IMTX, $AUTL)
✔ Precision oncology remains focused on increasingly defined patient populations ($BNTX, $BDTX, $AZN)
✔ Late-stage studies continue refining standards of care ($MRK, $NVS, $PFE, $INCY)
✔ Rare and difficult-to-treat tumors remain fertile ground for innovation ($COGT, $GSK, $IMNM, $INBX)
ASCO 2026 continues to showcase both technological innovation and the growing complexity of modern cancer treatment.
Don't Miss Any Upcoming Catalysts! The BPIQ catalyst calendar tracks every upcoming readout, PDUFA, and major medical conference across biopharma, in one place, updated daily, so you can spot the next move before it moves.
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 05/30/26 MD, RF
Comments